PATHFINDER 2: A Multi-Cancer Early Detection Study
Study Details
Study Description
Brief Summary
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America. The purpose of this study is to evaluate the safety and performance of the GRAIL MCED test in a population of individuals who are eligible for guideline-recommended cancer screening. In cases with a "cancer signal detected" test result, participants will undergo diagnostic procedures based on the test returned cancer signal origin(s) to determine if they have cancer. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test.
The study will enroll approximately 20,000 participants as defined by eligibility criteria over an anticipated enrollment period of approximately 18 months at up to 40 clinical institutions within North America. Participants will be actively followed for approximately 3 years from the date of their enrollment.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Participants 50 years of age or older The study will aim to enroll a diverse participant population generally representative of the US population with respect to race, ethnicity, and sex. The target age categories of 60-69 years and 70-79 years will be enriched to increase the number of cancer events that are observed during the study. |
Device: Multi-Cancer Early Detection Test
Blood collection and multi-cancer early detection testing with return of results.
|
Outcome Measures
Primary Outcome Measures
- Safety: Number and type of invasive procedures performed in participants with a cancer signal detected by the multi-cancer early detection (MCED) test and no cancer diagnosis at the time of diagnostic resolution (i.e., false positive test result). [Up to 3 Years]
- Test performance: diagnosis of invasive cancer, assessed by positive predictive value (PPV). [Up to 3 Years]
- Test performance: diagnosis of invasive cancer, assessed by negative predictive value (NPV). [Up to 3 Years]
- Test performance: diagnosis of invasive cancer, assessed by sensitivity. [Up to 3 Years]
- Test performance: diagnosis of invasive cancer, assessed by specificity. [Up to 3 Years]
- Test performance: diagnosis of invasive cancer, assessed by cancer signal origin (CSO) accuracy. [Up to 3 Years]
- Test performance: diagnosis of invasive cancer, assessed by observed cancer detection rate (CDR). [Up to 3 Years]
- Test performance: diagnosis of invasive cancer, assessed by number needed to screen to detect an invasive cancer (NNS). [Up to 3 Years]
Secondary Outcome Measures
- Participant-reported anxiety resulting from use of the multi-cancer early detection (MCED) test assessed via questionnaire at various time points during the study. [Up to 3 Years]
- Participant-reported intention to follow and use guideline recommended cancer screening procedures after use of the multi-cancer early detection (MCED) test assessed via questionnaire at various time points during the study. [Up to 3 Years]
- Cancer detection rate of confirmatory PET-CT in participants for whom cancer signal origin directed workups do not result in diagnosis of cancer. [Up to 3 Years]
- Number and type of diagnostic evaluations (imaging procedures, invasive procedures, laboratory test) by predicted cancer signal origin and outcome of diagnostic resolution. [Up to 3 Years]
- Per-participant radiation exposure during diagnostic evaluation for test positive participants. [Up to 3 Years]
- Accuracy of initial multi-cancer early detection (MCED) test result and cancer signal origin prediction, among the subset of participants with a research blood draw. [Up to 3 Years]
- Participants-reported perceptions about the multi-cancer early detection (MCED) test including satisfaction with the MCED tests and attitudes towards subsequent MCED testing assessed via questionnaire at various time points during the study. [Up to 3 Years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants must be at least 50 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
-
Participants must be capable of giving signed and legally effective informed consent
Exclusion Criteria:
-
Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
-
Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.
- Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
- Prior/Concurrent Concomitant Therapy (Medications/Treatments):
- Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date. Adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer) is not an exclusion criterion.
-
Individuals who will not be able to comply with the protocol procedures.
-
Individuals who are not currently registered patients at a participating center.
-
Previous or current participation in another GRAIL-sponsored study. "Participation" is defined as having signed consent and provided a blood sample.
-
Previous or current employees or contractors of GRAIL.
-
Current pregnancy (by self-report of pregnancy status)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sutter Health | Auburn | California | United States | 95602 |
2 | Sutter Health | Davis | California | United States | 95616 |
3 | Sutter Health | Elk Grove | California | United States | 95758 |
4 | Sutter Health | Fairfield | California | United States | 94534 |
5 | Sutter Health | Modesto | California | United States | 95355 |
6 | Sutter Health | Sacramento | California | United States | 95816 |
7 | Sarah Cannon Research Institute - Englewood Primary Care | Englewood | Colorado | United States | 80113 |
8 | Woodlands Medical Specialists | Pensacola | Florida | United States | 32503 |
9 | Ochsner Health | New Orleans | Louisiana | United States | 70127 |
10 | Maryland Oncology Hematology | Annapolis | Maryland | United States | 21401 |
11 | Henry Ford Macomb | Clinton Township | Michigan | United States | 48038 |
12 | Henry Ford Medical Center Ford Road | Dearborn | Michigan | United States | 48126 |
13 | Henry Ford Health System | Detroit | Michigan | United States | 48202 |
14 | Henry Ford Medical Center Harbortown | Detroit | Michigan | United States | 48207 |
15 | Henry Ford Medical Center Detroit North West | Detroit | Michigan | United States | 48235 |
16 | Henry Ford Medical Center Sterling Heights | Sterling Heights | Michigan | United States | 48310 |
17 | Mayo Clinic - Cancer Center | Rochester | Minnesota | United States | 55905 |
18 | Cleveland Clinic | Cleveland | Ohio | United States | 44195 |
19 | Oregon Health & Science University Bay Area Hospital | Coos Bay | Oregon | United States | 97420 |
20 | Oregon Health & Science University Knight Cancer Institute | Portland | Oregon | United States | 97201 |
21 | Sarah Cannon Research Institute - The Frist Clinic | Nashville | Tennessee | United States | 37203 |
22 | Texas Oncology - West Texas | Amarillo | Texas | United States | 79106 |
23 | Texas Oncology - Dallas Presbyterian | Dallas | Texas | United States | 75231 |
24 | Texas Oncology - Plano East | Plano | Texas | United States | 75075 |
25 | Texas Oncology - Plano West | Plano | Texas | United States | 75093 |
26 | Texas Oncology - Tyler | Tyler | Texas | United States | 75702 |
27 | Northwest Cancer Specialists | Vancouver | Washington | United States | 98684 |
Sponsors and Collaborators
- GRAIL, LLC
Investigators
- Study Director: Eric Fung, MD, PhD, GRAIL, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GRAIL-012